All In Biotech

Free tool

FAERS Monitor: Celestone Soluspan

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 014602 or its brand name (Celestone Soluspan, Betamethasone Acetate, Betamethasone Sodium Phosphate). Reports on generic versions are filed under their own applications.

Reports

397

Serious

177

45% of reports

Hospitalization

64

Death reported

9

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • maternal exposure during pregnancy122
  • product use in unapproved indication28
  • drug ineffective21
  • exposure during pregnancy20
  • no adverse event20
  • pain17
  • anxiety15
  • headache14
  • dizziness13
  • fatigue12
  • insomnia12
  • anaphylactic reaction11
  • dyspnoea11
  • nausea11
  • off label use11

Reports by year received

View as table
YearReports
20047
200519
200610
20074
20089
200916
20106
20117
20125
201316
201414
201511
201641
201724
201830
201940
202042
202137
202227
202314
20249
20253
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,762 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
maternal exposure during pregnancySignal12272.662.68,570
exposure during pregnancySignal2017.111.1287
anaphylactic reactionSignal1110.55.986
product use in unapproved indicationSignal286.04.2113
no adverse eventSignal205.83.876
anxietySignal152.81.716
insomniaSignal122.41.48
pain171.50.92
dizziness131.40.81
headache141.20.70
dyspnoea111.00.60
drug ineffective210.80.60
fatigue120.80.50
nausea110.70.41
off label use110.70.42

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.